Editorial
|
|
|
|
|
Hasty regulators gambled on aliskiren's harms and benefits
|
|
|
|
New Products
|
|
|
|
|
In kidney transplantation: more risky than ciclosporin
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fluticasone and infants : a poor example
|
|
|
|
|
|
|
|
|
|
Still no evidence that aliskiren reduces morbidity or mortality
|
|
|
|
|
|
|
|
|
|
No authorisation in the European Union
|
|
|
|
|
|
Adverse Effects
|
|
|
|
|
Avoid erythromycin and clarithromycin
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NSAIDs should not be used at any time during pregnancy
|
|
|
|
|
|
|
|
|
|
Unfavourable harm-benefit balance
|
|
|
|
|
|
|
|
|
|
3 times more reports involved pefloxacin
|
|
|
|
|
|
|
|
Outlook
|
|
|
|
|
Funding drug research independent of drug companies: a pipe dream or a public health necessity?
|
|
|
|
|
|
|
|
|
|
No correlation with therapeutic benefits
|
|
|
|
|
|